Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Post-transplant maintenance strategies in AML

Arnon Nagler • 14 Jun 2021
EHA 2021
Acute Myeloid Leukemia Leukemia Gilteritinib Sorafenib Venetoclax

Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses post-transplant maintenance strategies for patients with acute myeloid leukemia (AML), in particular highlighting recommendations from the Acute Leukemia Working Party on sorafenib for patients with mutant FLT3. Prof. Nagler also discusses preventative therapy with donor lymphocyte infusion (DLI) and the role of gilteritinib post-transplant. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Arnon Nagler

Molecular profiling and MRD are reshaping transplant decision-making in AML
3:19
Molecular profiling and MRD are reshaping transplant decision-making in AML
Arnon Nagler • 15 Jun 2026
EBMT analysis: alloSCT may overcome FLT3-ITD risk in CBFB::MYH11-positive AML
3:26
EBMT analysis: alloSCT may overcome FLT3-ITD risk in CBFB::MYH11-positive AML
Arnon Nagler • 15 Jun 2026
Targeted therapies and immunotherapy are redefining transplantation in AML
3:18
Targeted therapies and immunotherapy are redefining transplantation in AML
Arnon Nagler • 15 Jun 2026
Umbilical cord blood transplantation in adults: revisiting its role in modern practice
2:40
Umbilical cord blood transplantation in adults: revisiting its role in modern practice
Arnon Nagler • 15 Jun 2026

Related Videos

Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
4:04
Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
Anna Schuh • 16 Oct 2026
Understanding the CLL genome: current knowledge and remaining gaps
3:39
Understanding the CLL genome: current knowledge and remaining gaps
Anna Schuh • 16 Oct 2026
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals